Antibacterial agent 325

Antibacterial agent 325 (Compound 14a) (0.25-16 μg/mL) exerts potent broad-spectrum in vitro antibacterial activity, with particularly strong efficacy against methicillin-resistant Staphylococcus aureus (MIC = 0.25 μg/mL), Escherichia coli (MIC = 0.25 μg/mL), Klebsiella pneumonia (MIC = 0.5 μg/mL), and Acinetobacter
baumannii (MIC = 0.5 μg/mL)^[1].
Antibacterial agent 325 (0.5-128 μg/mL) exhibits very low hemolytic activity against human red blood cells, with hemolysis rates below 3% across tested concentrations up to 128 μg/mL^[1].
Antibacterial agent 325 (10-100 μg/mL; 24 h) shows low cytotoxicity towards LO2 human hepatocytes^[1].
Antibacterial agent 325 exhibits synergistic in vitro antibacterial activity with Norfloxacin (HY-B0132) against both E. coli and MRSA, with an FICI of 0.25 for both strains^[1].
Antibacterial agent 325 (0.25-1 μg/mL; 12 h) demonstrates rapid bactericidal activity against MRSA, with complete eradication of the strain within 12 h at 4× MIC^[1].
Antibacterial agent 325 (16 days) has a low potential to induce MRSA resistance, with no increase in MIC observed over 16 serial passages^[1].
Antibacterial agent 325 (0.25-1 μg/mL; 10-30 min) induces significant, time-dependent membrane depolarization in MRSA^[1].
Antibacterial agent 325 (0.25-1.5 μg/mL) disrupts the membrane integrity of MRSA in a dose-dependent manner, as shown by increased PI uptake and reduced calcein-AM retention^[1].
Antibacterial agent 325 (0.25-2 μg/mL) causes dose-dependent protein leakage from MRSA^[1].
Antibacterial agent 325 (0.25-2.5 μg/mL; 30-150 min) induces dose-dependent and time-dependent ROS production in MRSA^[1].
Antibacterial agent 325 (0.25-2 μg/mL) induces dose-dependent lipid peroxidation in MRSA^[1].
Antibacterial agent 325 (0.25-2 μg/mL) impairs the antioxidant defense system of MRSA cells, causing a dose-dependent loss of GSH activity^[1].
Antibacterial agent 325 (2 μg/mL; 6 h) causes visible morphological damage and shrinkage of MRSA^[1].
Antibacterial agent 325 (0.25-2 μg/mL) dose-dependently inhibits the metabolic activity of MRSA^[1].
Antibacterial agent 325 (0.25-2 μg/mL) dose-dependently inhibits MRSA LDH activity^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.